Coya Therapeutics (COYA) Net Margin (2023 - 2026)
Coya Therapeutics' (COYA) quarterly Net Margin came in at 2723.44% in Q2 2026, up 100173.0% year-over-year from N/an in Q2 2025, and up 5.09% quarter-over-quarter from 2869.63% in Q1 2026.
Powered by 
Analysis
Coya Therapeutics (COYA) Net Margin (2023 - 2026) Analysis & Trends
Coya Therapeutics has disclosed Net Margin across 4 years of filings, most recently posting 2723.44% for Q2 2026.
- In Q2 2026, Net Margin rose 100173.0% year-over-year to 2723.44%; the TTM figure through Jun 2026 stood at 278.2% (up 490121.0% YoY), while the FY2025 annual figure was 211.01%, up 13577.0% from the prior year.
- Net Margin came in at 2723.44% for Q2 2026 at Coya Therapeutics, up from 2869.63% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 30.24% in Q4 2023 to a low of 209031.51% in Q4 2024.
- Average Net Margin over 4 years is 22544.08%, with a median of 2778.4% recorded in 2026.
- Year-over-year, Net Margin slumped 20906175 bps in 2024 and jumped 20887921 bps in 2025.
- Over 4 years, Net Margin stood at 30.24% in 2023, then plunged by 691308 bps to 209031.51% in 2024, then surged by 100 bps to 152.3% in 2025, then sank by 1688 bps to 2723.44% in 2026.
- Per Business Quant data, the three most recent Net Margin figures were 2723.44% in Q2 2026, 2869.63% in Q1 2026, and 152.3% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.78 Bn | 192.79 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 179.92 Bn | 176.74 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 131.39 Bn | 123.54 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 60.35 Bn | 55.17 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 33.12 Bn | 29.81 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.92 Bn | 30.63 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 29.23 Bn | 29.23 Bn | 1.16 Mn | -20,152.98% |
| 10 | Coya Therapeutics | 105.32 Mn | 62.12 Mn | - | -2,723.44% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,723.44% |
| Mar 31, 2026 | -2,869.63% |
| Dec 31, 2025 | -152.30% |
| Sep 30, 2025 | -68.26% |
| Jun 30, 2025 | -3,725.17% |
| Mar 31, 2025 | -2,833.35% |
| Dec 31, 2024 | -209,031.51% |
| Jun 30, 2024 | -84.42% |
| Mar 31, 2024 | -3,982.96% |
| Dec 31, 2023 | 30.24% |